Normal Saline (IV Fluids) Manufacturing Market Research Report 2026: Size, Growth, Tier-2/3 Supply Gap and Business Opportunity for Startups in India

Normal saline is as close to a demand that cannot be killed as a medicine can be in India—nearly all hospitalised patients receive it, hospitalisations are increasing by 12-15% every year and it has been placed in the National List of Essential Medicines, which means that it must be available in every public hospital in the country. But India’s roughly ₹4,200 crore IV fluid market is controlled by only a handful of big manufacturers and hospitals in tier-2 and tier-3 towns experience frequent shortages and price variations. That’s a rare recipe for an entrepreneur – a known region-wide shortage of supply that isn’t being met by known established players.

What Is Normal Saline?

Normal saline is a sterile, 0.9 percent sodium chloride solution in water whose electrolyte content is similar to that of human blood plasma, and which is therefore considered isotonic and safe for direct intravenous injection. It is one of a group of crystalloid IV fluids (along with Ringer’s Lactate, dextrose solutions, and dextrose-saline combinations) which are the cornerstone of hospital fluid therapy. It has several major clinical applications such as:

• Intravenous fluid replacement/rehydration – for dehydration, blood loss and shock
• Diluents for medications: normal saline is the common carrier fluid used to inject many IV medications.
• Replacement of electrolytes and sodium – correcting hyponatremia and fluid-electrolyte balance – electrolyte and sodium replacement
• Wound irrigation and cleaning – sterile, physiologically compatible rinse for wound care
• Catheter and IV-line flushing – maintaining patency of vascular access devices
• Total parenteral nutrition (TPN) additive – as a base or carrier fluid component

Manufacturing is a pharmaceutical production process, which must be carried out under aseptic condition: Raw material procurement (Pharmaceutical grade sodium chloride and water for injection); Formulation preparation; Sterilisation; Filling and Sealing (into Flexible bags, Plastic bottles, Glass bottles, or ampoules); Packaging; Quality control (as per Schedule M Good Manufacturing Practice requirements in India).

Get Detailed Project Report (DPR): IV Fluids & Intravenous Solutions Manufacturing Guide

Global and India Normal Saline / IV Fluids Market Size and Growth

The global market value of normal saline ranges from USD 3.8–5.47 billion for 2024–25 (USD 6.93–8.41 billion by 2033–2035), depending on the scope of the category under consideration, and generally has a forecast compound annual growth rate (CAGR) of 4.4–6.97%. Nearly 89% of manufacturers use plastic bottles for packaging, as they offer greater resistance to breakage than glass bottles throughout the packaging supply chain.

The market for IV fluids, including normal saline, Ringer’s lactate, dextrose solutions, and other crystalloids, stands at around ₹4,200 crore and is expected to grow at a healthy rate of 9-10% annually. This growth aligns with the increase in hospital admissions in India, which experts expect to grow at a healthy rate of 12-15% annually. A separate 2021 estimate placed the Indian normal saline market at ₹6.8 billion, with a CAGR of 9.2% till 2026.

Note on figures: IV fluid market studies differ depending on whether they reflect normal saline, or the overall category of crystalloids/IV solutions. NPCS can create an investor-grade techno-economic feasibility study with the numbers for your selected product mix (normal saline, dextrose, Ringer’s Lactate) and your regional market.

The Tier-2/Tier-3 Supply Gap Behind a Consolidated National Market

The IV fluid sector in India is termed by industry sources as a “comparatively few large manufacturers” where the national manufacturers have their distribution and production centers aimed at metro and large institutions, resulting in a regional imbalance as smaller hospitals in tier-2 and tier-3 towns experience a shortage of IV fluids and frequent price changes.

This is further exacerbated by the fact that India’s National List of Essential Medicines (NLEM), a structural policy fact, obligates government hospitals to stock normal saline, dextrose and Ringer’s Lactate at all times. This guarantees a government institutional buyer for the new regional manufacturer. The manufacturer must supply the products reliably and in good quality.

IV fluids are highlighted in Invest India’s list of the best pharmaceutical companies to invest in. This is due to the preference they enjoy in government procurement through Jan Aushadhi and hospital formularies.

Policy Tailwinds

1. NLEM essential medicine status: Normal saline, dextrose, and Ringer’s Lactate are all classified as priority essential medicines, creating a guaranteed institutional demand floor from government hospitals required to maintain constant stock.
2. Jan Aushadhi Scheme and hospital formulary preference: Government procurement channels give preference to domestic IV fluid manufacturers, directly supporting new entrant market access.
3. Rising hospital bed capacity and healthcare infrastructure investment: With Indian hospital admissions growing 12-15% annually and continued expansion of both public and private healthcare infrastructure into smaller cities, underlying IV fluid demand is structurally assured.
4. Schedule M GMP and regulatory framework: While raising the compliance bar, India’s regulatory framework for pharmaceutical manufacturing also provides the quality assurance structure that positions compliant domestic manufacturers competitively against both informal alternatives and imports.
5. Government focus on domestic pharmaceutical manufacturing self-reliance: Broader Atmanirbhar Bharat and pharmaceutical PLI-adjacent policy priorities support import substitution and domestic capacity building across essential medicine categories, of which IV fluids are a clear beneficiary.

Get Detailed Insights from This Book: Biotech & Pharmaceutical Handbook

India Demand-Supply Gap: Normal Saline / IV Fluids

Reading the gap: This category resembles Hume pipes and PSC sleepers in structure — demand isn’t in question, and the technology is well understood by India’s existing pharmaceutical manufacturing base, but the market’s national consolidation leaves smaller regional hospital markets underserved. A regional GMP-compliant manufacturer, particularly one positioned to serve government hospital formulary requirements under NLEM obligations, can address a documented gap that large national players’ distribution economics haven’t prioritised closing.

Major IV Fluids/Normal Saline Manufacturers Serving India

Market Segmentation

Packaging Type

• Flexible bags — dominant globally, over 60% share, favoured for storage efficiency and reduced contamination risk
• Plastic bottles — nearly 89% share in some market definitions, favoured over glass for breakage prevention
• Glass bottles — niche applications, specialty pharmaceutical compounding
• Ampoules and vials — smaller-volume applications

Volume

• Below 250 mL
• 250-500 mL
• 500-1,000 mL — commonly used hospital ward volumes
• Above 1,000 mL

Application

• Intravenous fluid therapy (hydration, electrolyte replacement) — largest segment
• Drug dilution and reconstitution
• Fluid and electrolyte replacement
• Catheter and line flushing
• Wound irrigation

End User

• Hospitals — largest segment, with consumption roughly tracking bed count (an estimated 18 bottles per bed monthly is a commonly cited industry planning benchmark)
• Ambulatory surgical centres
• Clinics
• Home healthcare (a growing segment as care shifts toward outpatient and home settings)

Access Complete Business Plan: I.V. Fluid Manufacturing: Detailed Project Report & Business Plan

Key Growth Drivers

1. An increase in hospital admissions and growth in healthcare facilities. IV fluid demand is structurally linked to one of the most consistently growing sectors in India, as hospital admissions are increasing by 12-15% per year and the capacity of public and private hospitals continue to grow.
2. NLEM essential medicine status creating guaranteed government demand. Legal requirements for government hospitals to maintain constant stock of normal saline and related IV fluids provide a demand floor independent of broader market cyclicality.
3. Inconsistent increase of chronic diseases that need fluid management. More common diabetes, cancer and chronic disease directly contribute to the use of IV therapy in hospitals and more recently in home care.
4. Expansion of surgical and emergency care volumes. As India’s healthcare system handles growing surgical caseloads and emergency medical services activity, baseline crystalloid IV fluid consumption grows correspondingly.
5. Rise of home healthcare and outpatient infusion. Following a global trend toward decentralised care delivery, growing home healthcare adoption in India creates new, distributed demand points beyond traditional hospital settings.
6. Export competitiveness. Indian manufacturers demonstrated ability to export IV fluids to Africa, Southeast Asia, the Middle East, and Latin America on the basis of competitive costs and quality standards signals genuine domestic manufacturing capability beyond serving India’s own market.

Challenges and Restraints

• Tight regulatory compliance requirements. Pollution control approval and (if required for export markets) WHO-GMP certification, are real, non-negotiable investment and operational requirements — for smaller producers, the associated investment to comply with the standards (typically quoted as $2-3 million for a compliant setup elsewhere in the world) may be a significant hurdle.
• Competitive price and slim profit on commodity goods. The first two points to be competitive are to be able to supply the same IV fluids at a lower cost with sufficient volume and always in a reliable manner, which is why new players need to get efficient fast as IV fluids are basically undifferentiated pharmaceutical commodities.
• Disruption risk of raw materials and supply chain. Supply chain vulnerability can result in sudden disruptions in raw material supply or production capacity, as has been witnessed across the world during the COVID-19 pandemic; this is an important consideration for any manufacturer.
• Institutional supply contract dependency for profitability. Industry analysis states that the profitability of an IV manufacturing project depends on the plant operating at high capacity with guaranteed contract for institutional supply (hospital tenders, government procurement), hence contract securing is important to ensure project viability.
• Trend of balanced fluids. Manufacturers will consider long term product-mix as some clinical research has led to the use of “balanced” crystalloid fluids rather than “normal saline” in some applications.

Related Article: IV Fluids & Dialysis Industry Consultants in India: Your Complete Guide to Expert Project Consultancy

Competitive Landscape

The IV fluids market in India is dominated by a blend of large, well-established multinational companies (Baxter, B. Braun and ICU Medical mainly focussing on large institutional as well as metro market supply) and large domestic manufacturers (Claris Injectables and Denis Chem Lab) that serve the same major market segments. This is a true opportunity for the region to increase the number of GMP factories as the combination of this concentration at the top of the market and the well-known Tier-2/Tier-3 supply gap will definitely offer a chance for the region to enter this field with reliability and local presence as much or more important than brand scale, due to the necessity to fulfil NLEM obligations by securing government contracts for the procurement of hospitals.

Normal Saline Manufacturing: Business Opportunity for Startups and MSMEs

1. Regional GMP facility for preparing/manufacturing products for Tier-2 or Tier-3 hospitals. A manufacturer located in the region who has a steady supply and is Schedule M GMP compliant, directly serves an underserved market segment due to the documented scarcity and price volatility of smaller hospitals.
2. Government hospital procurement/NLEM orientated supply. Specifically oriented towards the government’s hospital tenders and Jan Aushadhi scheme requirements provides a structurally assured demand base as per a legal requirement to stock essential medicines.
3. Phased entry via IV administration sets before full IV fluid manufacturing. IV administration sets are a Class B medical device with a comparatively lower regulatory barrier than full parenteral drug manufacturing, offering a lower-capital entry point and a pathway to build hospital tender relationships before expanding into IV fluid production itself.
4. A product line that is diversified. Having the ability to provide all normal saline, dextrose solutions and Ringer’s Lactate in one relationship, not just normal saline, assists with manufacturing and sterilisation equipment.
5. Export-oriented manufacturing. Once a manufacturer holds WHO-GMP certification, they can expand their export market to Africa, Southeast Asia, Middle East, and Latin America as done by Indian manufacturers, and find meaningful export market.

Investment in IV fluid production is hefty and is not negotiable under the pharmaceutical GMP requirement, usually the investment in a medium scale plant is around ₹18-35 crore (capacity and degree of automation depends on the project) and the operating margins are usually around 12-18% depending on its capacity utilisation and secured institutional supply contracts. NPCS prepares detailed Project Reports with Schedule M GMP compliance guidance, machinery specifications and regional/institutional market assessment based on your target capacity and product mix to meet the project requirements.

Discover scalable startups tailored to your goals

How NPCS Supports Entrepreneurs Entering This Space

Before considering a normal saline/IV fluids manufacturing business, it is essential for the entrepreneur to prepare a Detailed Project Report (DPR) which covers aspects like plant capacity, the pathway for compliance with Schedule M GMP, raw material sourcing, manpower planning, project cost and financial viability related to the product mix and the target institutional market.

About NPCS (Niir Project Consultancy Services)

Founded in 1994, NPCS is an ISO 9001:2015 certified industrial consultancy based in New Delhi. It has more than three decades of experience in techno-economic & project consultancy.

In the past three decades, NPCS has successfully provided over 150,000 project reports and profiles in 85 countries. These cover most manufacturing and process industries, including pharmaceutical manufacturing, parenteral products and healthcare consumables.

Some of the main outputs of NPCS for a normal saline business are:

• Detailed Project Reports (DPRs) with plant capacity, machinery specification, layout etc.
• Techno-Economic feasibility studies including Schedule M GMP guidance was carried out.
• Financial modelling – project cost, profitability analysis, ROI and break-even calculations
• Raw Material & Market Feasibility for Indian regional market with Government procurement channels
• Support documents required for MSME loan applications, subsidy schemes and bank funding requirements

Government and Institutional Reference Links

Entrepreneurs can also connect with the Organisation of Pharmaceutical Producers of India (OPPI) and the Pharmaceuticals Export Promotion Council of India (Pharmexcil), a body sponsored by India’s Ministry of Commerce and Industry, for regulatory guidance, export documentation support, and industry networking specific to parenteral drug manufacturing.

1. Central Drugs Standard Control Organisation (CDSCO)
2. Ministry of Health & Family Welfare — National List of Essential Medicines (NLEM)
3. Pharmaceuticals & Medical Devices Bureau of India — Jan Aushadhi Scheme
4. Ministry of Micro, Small and Medium Enterprises (MSME)
5. Development Commissioner, MSME (DCMSME)
6. Central Pollution Control Board (CPCB)
7. Press Information Bureau (PIB), Government of India
8. Startup India
9. Invest India (National Investment Promotion and Facilitation Agency)

Entrepreneurs are advised to verify the latest Schedule M GMP requirements, NLEM procurement guidelines, and MSME subsidy norms directly on these portals, as regulatory provisions are periodically revised.

Conclusion

Normal saline is a market in Indian pharmaceutical manufacturing with an almost entirely non-discretionary demand. It also has a regionally persistent supply shortage that national manufacturers of normal saline have not filled.

For a start-up that is ready to invest in real Schedule M GMP compliance, this is the category where the business risk is not the lack of demand. The real risk is execution. This includes getting a supply contract at an institutional level. It also includes developing a production capability that is reliable and of good quality. This is what tier-2 and tier-3 hospitals are currently missing.

Normal saline and IV fluids generally have a structurally ensured demand base. This demand is supported by India’s expanding hospital network and the critical requirement for these fluids. For entrepreneurs and MSMEs considering investments in pharmaceutical manufacturing, this represents an assured market segment. It is supported by hospital infrastructure and its procurement needs.